About YD Bio Limited Warrants
https://www.ydesgroup.comYD Bio Ltd. engages in the development of detection and therapeutic technologies. It offers cancer detection products, regenerative ophthalmology products, and exosome science. The company was founded on February 6, 2024 and is headquartered in Taipei, Taiwan.
CEO
Russell D. Griffin
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public August 29, 2025
Full time employees 4
Ratings Snapshot
Rating : C+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 5
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $3.45 M
52w High $1.00
52w Low $0.98
P/E 0
Volume 3.28K
Outstanding Shares 3.31M
About YD Bio Limited Warrants
https://www.ydesgroup.comYD Bio Ltd. engages in the development of detection and therapeutic technologies. It offers cancer detection products, regenerative ophthalmology products, and exosome science. The company was founded on February 6, 2024 and is headquartered in Taipei, Taiwan.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 | $389.19K ▲ | $-2.21M ▲ | 0% | $-0.65 ▲ | $-2.22M ▲ |
| Q1-2025 | $0 | $353.82K ▼ | $-3.37M ▼ | 0% | $-0.98 ▼ | $-3.37M ▼ |
| Q4-2024 | $0 | $381.29K | $417.79K | 0% | $0.1 | $417.79K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $469.52K | $5.84M | $752.93K | $5.09M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-2.21M ▲ | $-298.19K ▲ | $557.48K ▼ | $-253.38K ▲ | $5.91K ▲ | $-298.19K ▲ |
| Q1-2025 | $-3.37M ▼ | $-490.41K ▼ | $7.28M ▲ | $-6.89M ▼ | $-101.27K ▼ | $-490.41K ▼ |
| Q4-2024 | $417.79K | $-365.65K | $168.39K | $298.94K | $101.67K | $-365.65K |
CEO
Russell D. Griffin
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public August 29, 2025
Full time employees 4
Ratings Snapshot
Rating : C+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 5
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0